Human DNA polymerase b (polb) is a small, monomeric protein essential for short-
Therefore, aberrant expression of miRNAs may lead to the development and progression of cancer, and have prognostic significance for several tumour types. [13] [14] [15] [16] DNA polymerase b (polb) is a member of the DNA polymerase family and is essential for base excision repair (BER), one of the major pathways of DNA repair. [17] [18] [19] [20] [21] Thirty percent of all tumours reported to date harbour mutations in the polb gene. 22 Aberrant polb expression results in an increased rate of spontaneous mutagenesis, and a highly mutagenic phenotype. 23, 24 Studies have reported polb mutations in various cancer types, and have shown that this may play a role in mediating tumour sensitivity to cisplatin. [25] [26] [27] [28] [29] Esophageal cancer (EC) is a major cause of cancer-related deaths worldwide. Many previous studies have reported that the polb gene is often mutated in primary EC tissues. EC also exhibits varying degrees of sensitivity to chemotherapy in the clinic. Previously, we performed miRNA chip-based expression analysis of EC tissues and found that the expression of miR-149 in EC tissues was aberrant.
Based on bioinformatic analyses, we hypothesized that the human polb 3 0 UTR contains the putative binding sites for miR-149, and that miR-149 may affect the sensitivity of EC cell lines to cisplatin.
In this study, we first investigated whether miR-149 modulates polb expression, and then examined the influence of miR-149 on cisplatin sensitivity in EC cell lines. We identified a novel homozygous C to G point mutation at nucleotide 1134 (C1134G) in the polb gene of EC patient tissues, and analysed the relationship between C1134G polb and miR-149.
| MATERIALS AND METHODS

| Patients and tissue specimens
Specimens were collected from a total of 82 EC patients with TNM stage III between 2011 and 2015, from the First Affiliated Hospital of Zhengzhou University and the Oncology Hospital of Linzhou City.
All specimens were obtained using endoscopy and biopsy assays.
Patients received chemotherapy with cisplatin (100 mg/m 2 body surface area; Day 1) and 5-FU (1000 mg/m 2 body surface area; Days 1-5), repeated every 28 days; none had received chemotherapy or radiotherapy prior to surgery. The patients were followed for a minimum of 36 months. All patients were informed in advance and signed explicit informed consent forms. This study was approved by the ethics committee of Zhengzhou University. 
| Lentivirus production and infection of cells
Full-length pre-miR-149 and scramble-miR-149 were generated by PCR amplification from pUC18-miR-149 or pUC18-scramble-miR-149
vector. The fragments were cloned into the lentiviral vector (LV5) under control of the EF-1a promoter to construct the expression vectors LV5-miR-149 and LV5-miR-NC (Control). We co-transfected the 
| CCK-8 assay
Cells were transferred to 96-well plate at a density of 1 9 10 4 cells/ well, with five replicate wells per group. Next, the cells were treated with 0-30 lmol/L cisplatin (dissolved in NaCl, stored at À20°C).
After 48 hours, the relative numbers of viable cells were detected using Cell Counting Kit-8 reagents (CCK-8; Dojindo, Japan). Results were recorded using a microplate reader (Elx800; BioTek, VT, USA), with the absorbance optical density at 450 nm, and the IC50 was calculated. The experiments were done in triplicate.
| Flow cytometry assay
The 
| Caspase3/7 activity assay
Cells from each treatment group were harvested at 48 hours posttransfection and caspase activity was measured using a caspase activity assay kit (Beyotime, Haimen, China). Cellular extracts and substrates (Ac-DEVD-pNA) were kept in 96-well plate for 2 hours at 37°C. Absorbance values were measured using a microplate reader at 405 nm (Infinite M200, Tecan, Switzerland).
| Immunofluorescence microscopy
Immunofluorescence was performed to observe the expression level of c-H2AX in the nuclei of cells in different treatment groups. The cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature and permeabilized with 0.1% Triton X-100. After blocking in PBS containing 5% BSA for 1 hours, the cells were incubated with anti-c-H2AX primary antibodies and stained with FITC-conjugated secondary antibodies. Nuclei were stained with DAPI for 15 minutes. The mean number of immunostained nuclei per high-power field was determined using immunofluorescence microscopy. Results are presented as the average of at least three fields.
| DNA sequencing analysis
PCR-amplified fragments were cloned into pGEM-T vectors and transformed into Escherichia coli DH5a, which were grown at 37°C
to mid-log phase. The DH5a transformants were subjected to sequencing analysis at Sangon Biotech (Shanghai).
| Surface plasmon resonance
The binding ability of miR-149 and polb was tested by Surface
Plasmon Resonance (SPR) using a Biacore T200 instrument (Biacore, GE Healthcare). Biotinylated miR-149 and miR-NC were pur- 
| Statistical analysis
Statistical analysis was performed using SPSS 21.0 software. Data were expressed as the mean AE standard deviation. The t-test was used for comparison of means from different samples. The follow-up data were analysed using the Kaplan-Meier method and log-rank test. P < .05 was considered statistically significant. | 3859 Figure 1A ). In addition, the expression levels of polb mRNA in the tumour tissues of cisplatin insensitive patients was higher than that of cisplatin sensitive patients (P < .05, Figure 1B) . Conversely, the expression levels of miR-149 in tumour tissues were significantly lower than in adjacent non-tumour tissues (P < .05, Figure 1C) .
Furthermore, the expression levels of miR-149 in the tumour tissues of cisplatin in-sensitive patients were lower than that of cisplatin sensitive patients (P < .05, Figure 1D ). We also investigated the correlation between polb and miR-149 expression, and found that polb mRNA expression levels were increased in the EC tumour tissues, whereas miR-149 expression was reduced, demonstrating a significant negative correlation (R 2 = 0.623, P < .05, Figure 1E ).
The Kaplan-Meier method was used to analyse the difference in survival rates between the patients with high and low expression levels of polb mRNA or miR-149 (median value was chosen as the boundary of high and low expression), based on follow-up visits of EC patients. Patients with low expression levels of polb mRNA or high miR-149 survived longer than patients with high polb mRNA or low miR-149 (P < .05, Figure 1F ,G).
| Polb is identified as a target gene of miR-149 in EC1 and EC9706 cell lines
Bioinformatics analysis by TargetScan and miRanda predicted that the 3 0 UTR of polb contained binding sites for miR-149 ( Figure 2A ). polb protein expression levels in miR-149 group cell was significant lower than that in Blank and miR-NC groups (P < .05).
To verify whether polb is a direct target of miR-149, we used a Dual-Luciferase reporter system containing either the wild-type or the mutant 3 0 UTR of polb. There was no significant difference in luciferase activity between cells transfected with miR-NC and those co-transfected with miR-149 mimic and mutant-type 3 0 UTR of polb ( Figure 2C,D) . However, the luciferase activity of cells co-transfected with miR-149 mimic and wild-type 3 0 UTR of polb was significantly decreased (P < .05, Figure 2C ,D). These results indicate that miR-149 negatively regulates polb expression by directly binding to the putative binding sites in the 3 0 UTR.
| Cisplatin-induced proliferation inhibition was enhanced by miR-149 in EC1 and EC9706 cell lines
The relative expression of miR-149 in different cell lines is presented in Figure 3A . The expression of miR-149 was higher in the miR-149 group compared to the Blank and miR-NC groups (P < .05). The cell survival rate curves are presented in Figure 3B ,C.
Cell viability in all groups decreased with increasing doses of cisplatin. The viability of cells in the miR-149 group was significantly lower than that of the Blank and NC groups, across cisplatin doses (P < .05, Figure 3B ,C). The IC50 of cisplatin in EC1 and EC9706 cells was calculated, and this is shown in Figure 3D . The IC50 of cisplatin in the miR-149 cells was lower than that of the Blank and NC groups (P < .05).
F I G U R E 1 polb and miR-149 are associated with chemotherapy sensitivity and survival time in EC patients. A and B, The expression levels of polb mRNA in EC specimens. HET-1A cell line was used as untreated control. C and D, The expression levels of miR-149 in EC specimens. HET-1A cell line was used as untreated control. E, Correlation between polb mRNA and miR-149 in EC tumour tissues. F and G, Survival rates between the patients with high and low expression levels of polb mRNA or miR-149 in EC patients. *P < .05
| Cisplatin-induced apoptosis was enhanced by miR-149 in EC1 and EC9706 cell lines
Flow cytometry results indicated that treatment with cisplatin increased apoptosis in both the miR-NC and miR-149 cells. In addition, apoptosis in the miR-149 cells was significantly greater than that in the miR-NC cells (P < .05; Figure 4A ). In addition, after treatment with cisplatin, caspase 3/7 activity in the miR-149 cells was significantly higher than in the miR-NC cells (P < .05; Figure 4B ).
Western blotting showed that the expression of cleaved PARP was also significantly increased in miR-149 cells treated with cisplatin (P < .05; Figure 4C ). Immunofluorescence microscopy results indicated that the expression level of c-H2AX in the nuclei of miR-149 cells treated with cisplatin was significantly higher than that of miR-NC cells treated with cisplatin, and miR-NC or miR-149 cells without cisplatin (P < .05; Figure 4D ). These results indicated that miR-149 could enhance the apoptotic effects of cisplatin in EC1 and EC9706 cell lines.
| Expression of polb restored the function of miR-149
As discussed above, the exogenous expression of miR-149 enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in EC1 and EC9706 cell lines (Figures 3 and 4) . Therefore, we exogenously expressed recombinant polb lacking the 3 0 UTR miR-149 on EC1 and EC9706 cell lines that treated with cisplatin (P < .05, Figure 5B ).
| miR-149 did not regulate the C1134G variant of polb in EC tissues
We have shown that the expression level of miR-149 in the tumour tissues was significantly lower than in adjacent non-tumour tissues, and that polb mRNA expression in tumour tissues was significantly higher than in adjacent non-tumour tissues (P < .05, Figure 1A ,C).
Interestingly, in one sample (No. 22), the expression levels of miR-149 in the tumour tissue were not lower, and polb expression in the tumour tissue was higher, compared to the adjacent non-tumour tissue ( Figure 6A-C) . Using a DNA sequencing assay, we analysed the polb DNA sequence of sample No. 22 and identified a novel homozygous C to G point mutation at nucleotide 1134 ( Figure 6D ).
To further analyse the binding properties of polb with miR-149, surface plasmon resonance analysis was performed. BIAcore analysis confirmed that the binding affinity of miR-149 and wild-type polb is stronger than that of the miR-149 and C1134G variants of polb, and much stronger than that of the miR-149 and mutant-type polb, or the miR-NC and polb variants ( Figure 6E ).
To verify the relationship between the C1134G variant of polb and miR-149, we conducted a Dual-Luciferase reporter assay in DNA polymerase b (polb) is a key enzyme in the DNA damage repair system. This system serves as a crucial factor in maintaining genome integrity and stability, in addition to modulating the chemotherapy sensitivity of tumour cells. Many studies demonstrated that the polb is required for cisplatin sensitivity. 34, 35 Not surprisingly, polb has become a research hot spot worldwide.
miRNAs have been estimated to regulate up to 30% of human genes and control a variety of cellular processes. 36 Recent studies have shown that miRNAs are dysregulated in various cancers, and that their expression is relevant to a diverse array of tumours. 37, 38 In this study, we determined that the expression levels of polb mRNA in tumour tissues were significantly higher than that in adjacent non-tumour tissues. Interestingly, the expression levels of polb mRNA in the tumour tissues of cisplatin insensitive patients were higher than in cisplatin sensitive patients, and the expression level of miR-149 in the EC tumour tissues was inverse to that of polb. Our study revealed that polb mRNA expression levels were increased, where miR-149 mRNA expression levels were reduced, demonstrat- cells.
In conclusion, this study confirms that miR-149 may enhance cisplatin sensitivity in EC cell lines by targeting polb. In addition, we identified a new variant of polb (C1134G) and found that miR-149 may be unable to regulate the C1134G variant of polb. Based on these findings, potential drugs could be developed with a focus on enhanced sensitivity of EC patients to chemotherapy.
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